Revive Therapeutics (FRA:31R) 3-Year Book Growth Rate: 0.00% (As of Mar. 2026)


What is Revive Therapeutics 3-Year Book Growth Rate?

Revive Therapeutics FRA:31R +25.00% 3-Year Book Growth Rate is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 914 Drug Manufacturers companies, Revive Therapeutics ranks worse than 109409.08% on this metric.

Revive Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was €-0.01.

During the past 12 months, Revive Therapeutics's average Book Value per Share Growth Rate was -147.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Revive Therapeutics was 86.60% per year. The lowest was -43.60% per year. And the median was -8.55% per year.

Revive Therapeutics  (FRA:31R) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Revive Therapeutics 3-Year Book Growth Rate Related Terms

FRA:31R vs ZTS: 3-Year Book Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revive Therapeutics 3-Year Book Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's 3-Year Book Growth Rate falls into.


Revive Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Revive Therapeutics (FRA:31R) has a 3-Year Book Growth Rate of 0.00% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Revive Therapeutics and its competitors. According to the industry distribution chart, Revive Therapeutics ranks #999999 out of 914 companies in the Drug Manufacturers industry.
Is Revive Therapeutics' 3-Year Book Growth Rate too high?
Revive Therapeutics' current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, Revive Therapeutics ranks #999999 out of 914 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Revive Therapeutics' 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Revive Therapeutics ranks #999999 out of 914 companies for 3-Year Book Growth Rate. This places Revive Therapeutics in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 914 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Revive Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revive Therapeutics's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (FRA:31R) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Revive Therapeutics (FRA:31R), the current 3-Year Book Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revive Therapeutics Business Description

Other Exchanges RVVTF:USARVV:Canada
Address 82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.